Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Genprex, Inc.
organization4 mentionslast seen Nov 5, 2026
Biopharmaceutical company developing gene therapies for cancer and diabetes.
Relationships 5
- Genprex, Inc.developsREQORSA99% confidence4 sources
- Genprex, Inc.employsRyan M. Confer99% confidence4 sources
- Genprex, Inc.employsMark S. Berger97% confidence1 source
- Genprex, Inc.partners withMeharry Medical College92% confidence1 source
- Genprex, Inc.partners withMeharry Medical College90% confidence1 source
Relationship
Genprex, Inc.developsREQORSA
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 5, 2026Genprex, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Genprex, Inc. ("Genprex" or the "Company") issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product
- filingSEC EDGARNov 4, 2026Genprex, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product
- filingSEC EDGAROct 28, 2026Genprex, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Genprex's lead oncology candidate REQORSA
- filingSEC EDGAROct 21, 2026Genprex, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
TUSC2 is the therapeutic gene used in Genprex's investigational REQORSA® gene therapy, which is being developed for the treatment of cancer